Search Results - "Zhu, Shuangli"

Refine Results
  1. 1

    Combination strategies with PD-1/PD-L1 blockade: current advances and future directions by Yi, Ming, Zheng, Xiaoli, Niu, Mengke, Zhu, Shuangli, Ge, Hong, Wu, Kongming

    Published in Molecular cancer (21-01-2022)
    “…Antibodies targeting programmed cell death protein-1 (PD-1) or its ligand PD-L1 rescue T cells from exhausted status and revive immune response against cancer…”
    Get full text
    Journal Article
  2. 2

    Developing a hybrid model of Jaya algorithm-based extreme gradient boosting machine to estimate blast-induced ground vibrations by Zhou, Jian, Qiu, Yingui, Khandelwal, Manoj, Zhu, Shuangli, Zhang, Xiliang

    “…Blasting is still being considered to be one the most important applicable alternatives for conventional excavations. Ground vibration generated due to…”
    Get full text
    Journal Article
  3. 3

    Estimation of the TBM advance rate under hard rock conditions using XGBoost and Bayesian optimization by Zhou, Jian, Qiu, Yingui, Zhu, Shuangli, Armaghani, Danial Jahed, Khandelwal, Manoj, Mohamad, Edy Tonnizam

    Published in Underground space (Beijing) (01-10-2021)
    “…The advance rate (AR) of a tunnel boring machine (TBM) under hard rock conditions is a key parameter in the successful implementation of tunneling engineering…”
    Get full text
    Journal Article
  4. 4

    Recent advances in targeted strategies for triple-negative breast cancer by Zhu, Shuangli, Wu, Yuze, Song, Bin, Yi, Ming, Yan, Yuheng, Mei, Qi, Wu, Kongming

    Published in Journal of hematology and oncology (28-08-2023)
    “…Triple-negative breast cancer (TNBC), a highly aggressive subtype of breast cancer, negatively expresses estrogen receptor, progesterone receptor, and the…”
    Get full text
    Journal Article
  5. 5

    Predicting tunnel squeezing using support vector machine optimized by whale optimization algorithm by Zhou, Jian, Zhu, Shuangli, Qiu, Yingui, Armaghani, Danial Jahed, Zhou, Annan, Yong, Weixun

    Published in Acta geotechnica (01-04-2022)
    “…The squeezing behavior of surrounding rock can be described as the time-dependent large deformation during tunnel excavation, which appears in special…”
    Get full text
    Journal Article
  6. 6

    Combine and conquer: manganese synergizing anti-TGF-β/PD-L1 bispecific antibody YM101 to overcome immunotherapy resistance in non-inflamed cancers by Yi, Ming, Niu, Mengke, Zhang, Jing, Li, Shiyu, Zhu, Shuangli, Yan, Yongxiang, Li, Ning, Zhou, Pengfei, Chu, Qian, Wu, Kongming

    Published in Journal of hematology and oncology (15-09-2021)
    “…Our previous work showed that the anti-TGF-β/PD-L1 bispecific antibody YM101 effectively overcame anti-PD-L1 resistance in immune-excluded tumor models…”
    Get full text
    Journal Article
  7. 7

    Microenvironment responsive nanocomposite hydrogel with NIR photothermal therapy, vascularization and anti-inflammation for diabetic infected wound healing by Zhu, Shuangli, Zhao, Bangjiao, Li, Maocai, Wang, Hao, Zhu, Jiayi, Li, Qingtao, Gao, Huichang, Feng, Qi, Cao, Xiaodong

    Published in Bioactive materials (01-08-2023)
    “…Bacterial infection, excessive inflammation and damaging blood vessels network are the major factors to delay the healing of diabetic ulcer. At present, most…”
    Get full text
    Journal Article
  8. 8

    Recent advances and challenges of bispecific antibodies in solid tumors by Wu, Yuze, Yi, Ming, Zhu, Shuangli, Wang, Haiyong, Wu, Kongming

    Published in Experimental hematology & oncology (18-12-2021)
    “…Cancer immunotherapy has made remarkable progress in the past decade. Bispecific antibodies (BsAbs) have acquired much attention as the next generation…”
    Get full text
    Journal Article
  9. 9
  10. 10

    Combination of oral STING agonist MSA-2 and anti-TGF-β/PD-L1 bispecific antibody YM101: a novel immune cocktail therapy for non-inflamed tumors by Yi, Ming, Niu, Mengke, Wu, Yuze, Ge, Hong, Jiao, Dechao, Zhu, Shuangli, Zhang, Jing, Yan, Yongxiang, Zhou, Pengfei, Chu, Qian, Wu, Kongming

    Published in Journal of hematology and oncology (08-10-2022)
    “…Abstract Background Non-inflamed tumors, including immune-excluded and immune-desert tumors, are commonly resistant to anti-PD-1/PD-L1 (α-PD-1/PD-L1) therapy…”
    Get full text
    Journal Article
  11. 11

    Anti-TGF-β/PD-L1 bispecific antibody promotes T cell infiltration and exhibits enhanced antitumor activity in triple-negative breast cancer by Yi, Ming, Wu, Yuze, Niu, Mengke, Zhu, Shuangli, Zhang, Jing, Yan, Yongxiang, Zhou, Pengfei, Dai, Zhijun, Wu, Kongming

    Published in Journal for immunotherapy of cancer (01-12-2022)
    “…BackgroundAgents blocking programmed cell death protein 1/programmed death-ligand 1 (PD-1/PD-L1) have been approved for triple-negative breast cancer (TNBC)…”
    Get full text
    Journal Article
  12. 12

    MiRNA-mediated EMT and CSCs in cancer chemoresistance by Dong, Bing, Li, Shiyu, Zhu, Shuangli, Yi, Ming, Luo, Suxia, Wu, Kongming

    Published in Experimental hematology & oncology (12-02-2021)
    “…Cancer stem cells (CSCs) are a small group of cancer cells, which contribute to tumorigenesis and cancer progression. Cancer cells undergoing…”
    Get full text
    Journal Article
  13. 13

    Identification of MTHFD2 as a prognostic biomarker and ferroptosis regulator in triple-negative breast cancer by Zhang, Hao, Zhu, Shuangli, Zhou, Haiting, Li, Rui, Xia, Xiaohui, Xiong, Huihua

    Published in Frontiers in oncology (16-01-2023)
    “…Methylenetetrahydrofolate dehydrogenase 2 (MTHFD2) is a mitochondrial bifunctional enzyme encoded in the nucleus. It plays a significant role in the regulation…”
    Get full text
    Journal Article
  14. 14

    Persistent circulation of Coxsackievirus A6 of genotype D3 in mainland of China between 2008 and 2015 by Song, Yang, Zhang, Yong, Ji, Tianjiao, Gu, Xinrui, Yang, Qian, Zhu, Shuangli, Xu, Wen, Xu, Yi, Shi, Yong, Huang, Xueyong, Li, Qi, Deng, Hong, Wang, Xianjun, Yan, Dongmei, Yu, Wei, Wang, Shuang, Yu, Deshan, Xu, Wenbo

    Published in Scientific reports (14-07-2017)
    “…A total of 807 entire VP1 sequences of Coxsackievirus A6 (CV-A6) from mainland of China from 1992 to 2015, including 520 in this study and 287 from the GenBank…”
    Get full text
    Journal Article
  15. 15
  16. 16

    Focal adhesion kinase: from biological functions to therapeutic strategies by Tan, Ximin, Yan, Yuheng, Song, Bin, Zhu, Shuangli, Mei, Qi, Wu, Kongming

    Published in Experimental hematology & oncology (25-09-2023)
    “…Focal adhesion kinase (FAK), a nonreceptor cytoplasmic tyrosine kinase, is a vital participant in primary cellular functions, such as proliferation, survival,…”
    Get full text
    Journal Article
  17. 17

    Detection of multiple viruses potentially infecting humans in sewage water from Xinjiang Uygur Autonomous Region, China by Yang, Qian, Rivailler, Pierre, Zhu, Shuangli, Yan, Dongmei, Xie, Na, Tang, Haishu, Zhang, Yong, Xu, Wenbo

    Published in The Science of the total environment (01-02-2021)
    “…The progress of sequencing technologies has facilitated metagenomics projects on environmental samples like sewage water. The present study concerned the…”
    Get full text
    Journal Article
  18. 18

    The prospect of combination therapies with the third-generation EGFR-TKIs to overcome the resistance in NSCLC by Li, Shiyu, Zhu, Shuangli, Wei, Hongqu, Zhu, Pengfei, Jiao, Ying, Yi, Ming, Gong, Juejun, Zheng, Kun, Zhang, Li

    Published in Biomedicine & pharmacotherapy (01-12-2022)
    “…Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) bring significant benefits to non-small cell lung cancer patients with EGFR mutations,…”
    Get full text
    Journal Article
  19. 19

    Prevalence of multiple enteroviruses associated with hand, foot, and mouth disease in Shijiazhuang City, Hebei province, China: outbreaks of coxsackieviruses a10 and b3 by Tian, Huifang, Zhang, Yong, Sun, Qiang, Zhu, Shuangli, Li, Xiujuan, Pan, Zhuo, Xu, Wenbo, Xu, Baohong

    Published in PloS one (02-01-2014)
    “…Hand, foot, and mouth disease (HFMD) has been one of the most common infectious diseases in Shijiazhuang City, as is the situation in China overall. In the…”
    Get full text
    Journal Article
  20. 20

    The landscape of chimeric antigen receptor T cell therapy in breast cancer: Perspectives and outlook by Zhang, Hao, Zhu, Shuangli, Deng, Wanjun, Li, Rui, Zhou, Haiting, Xiong, Huihua

    Published in Frontiers in immunology (22-07-2022)
    “…Chimeric antigen receptor-T (CAR-T) cell therapy is a revolutionary adoptive cell therapy, which could modify and redirect T cells to specific tumor cells…”
    Get full text
    Journal Article